T2 Biosystems
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 113
- Market Cap
- -
- Introduction
T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)โข Click on a phase to view related trials
T2Resistance - Detection of Resistance Related Genes
- Conditions
- Resistance Bacterial
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- T2 Biosystems
- Target Recruit Count
- 1566
- Registration Number
- NCT05231187
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธZuckerberg San Francisco General Hospital, San Francisco, California, United States
๐บ๐ธTampa General Hospital, Tampa, Florida, United States
Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel
- Conditions
- Lyme Disease
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- T2 Biosystems
- Target Recruit Count
- 18
- Registration Number
- NCT03581279
- Locations
- ๐บ๐ธ
South County Internal Medicine, Wakefield, Rhode Island, United States
๐บ๐ธGundersen Health System, La Crosse, Wisconsin, United States
T2Bacteria Panel Pivotal Study
- Conditions
- Bacteremia
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- T2 Biosystems
- Target Recruit Count
- 2430
- Registration Number
- NCT02535468
- Locations
- ๐บ๐ธ
Henry Ford Health System, Detroit, Michigan, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธRhode Island Hospital, Providence, Rhode Island, United States
Serial Therapeutic and Antifungal Monitoring Protocol
- Conditions
- Candidemia
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- T2 Biosystems
- Target Recruit Count
- 31
- Registration Number
- NCT02163889
- Locations
- ๐บ๐ธ
University of Alabama, Birmingham, Alabama, United States
๐บ๐ธUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธRhode Island Hospital, Providence, Rhode Island, United States
Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)
- Conditions
- Bacteremia
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- T2 Biosystems
- Target Recruit Count
- 156
- Registration Number
- NCT01919762
- Locations
- ๐บ๐ธ
Cooper Medical School, Camden, New Jersey, United States
- Prev
- 1
- 2
- Next
News
Lyme Disease Pipeline Shows Promise with 7+ Therapies in Development as Valneva-Pfizer Vaccine Advances
DelveInsight's 2025 pipeline report identifies 7+ companies developing novel Lyme disease therapies, with emerging treatments including BLB 400, FP-100, CT38, TP-05, and VLA15 expected to significantly impact the market.
T2 Biosystems' T2Candida Panel Receives FDA Clearance for Pediatric Use
T2 Biosystems has received FDA clearance to market its T2Candida Panel for pediatric patients, expanding its availability to over 200 childrenโs hospitals in the U.S.
T2 Biosystems' T2Candida Panel Receives FDA Clearance for Pediatric Use
T2 Biosystems has secured FDA clearance to market its T2Candida Panel for pediatric patients, expanding its reach to over 200 children's hospitals in the U.S.
T2 Biosystems Advances Diagnostic Pipeline for AMR, Pediatric Infections, Lyme Disease, and Candida auris
T2 Biosystems is finalizing its 510(k) application for the T2Resistance Panel, aiming for FDA submission in Q4 2024 to combat antimicrobial resistance.